21Apr 2025
Proactive Monitoring Reduces Risk of Inflammation in Brolucizumab-Treated nAMD and PCV Patients

Proactive Monitoring Reduces Risk of Inflammation in Brolucizumab-Treated nAMD and PCV Patients

A retrospective study of 144 eyes treated with Brolucizumab for resistant nAMD and PCV found intraocular inflammation in 4.9% of cases. Proactive monitoring and early steroid intervention ensured favorable visual outcomes, underscoring the safety of Brolucizumab when carefully managed.

  • #ophthalmology

Like

Save

Share